Subventions et des contributions :
Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019).
Aspect Biosystems Ltd. ("Aspect") is a Vancouver-based biotechnology company pioneering the developmentx000D
and commercialization of novel 3D bioprinting technology. Bioprinting meniscal tissue is an application ofx000D
Aspect's technology with substantial potential for clinical application. The goal of this project is to applyx000D
mechanical testing protocols using the Mach-1TM mechanical test system (Biomomentum, Laval, Quebec) tox000D
successive iterations of bioprinted meniscal grafts. These protocols, developed under our original Engagex000D
application, will determine the suture pull-out strength, tensile strength, and compressive stiffness of thex000D
meniscal grafts. This is a critical step in the development of a successful meniscal graft.